Related Experiment Video
Updated: Nov 19, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
[Oncolytic adenovirus expressing CCL19 enhances immunity against gastric cancer in mice]
Zheng Chen1, Jiheng Liu1, Dayong Xu2
1Department of General Surgery, Changsha First Hospital, Changsha 410005, China.
Abstract:
Objective To explore whether oncolytic adenovirus expressing CCL19 can inhibit the growth of gastric cancer cells and activate anti-tumor immune response. Methods Mouse CCL19 gene was inserted into the E3 region of oncolytic adenovirus Ad5 to obtain engineered oncolytic adenovirus Ad5-CCL19. The expression of CCL19 in Ad5-CCL19-infected mouse MFC cells was detected by Western blotting. The effects of Ad5-CCL19 on the proliferation of MFC cells, MGC803 cells and BGC823 cells were tested by MTT assay. The anti-tumor activity of Ad5-CCL19 in vivo was examined by MFC cell subcutaneous transplantation tumor model. Immunofluorescence histochemical staining was used to detect CD4 and CD8 expression in tumor tissue. The secretion levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in tumor infiltrating T cells were detected by flow cytometry. Results Ad5-CCL19 could effectively infect MFC cells to secrete CCL19. Also, Ad5-CCL19 could induce significant dose-dependent cytotoxicity against target cells in vitro. The experiment in vivo showed that Ad5-CCL19 had stronger inhibitory effects on MFC cell tumor than Ad5 in the mice, and it could effectively enhance the infiltration of CD4+ T cells and CD8+ T cells and increase the secretion of IFN-γ and TNF-α in tumor tissues. Conclusion Ad5-CCL19 can significantly infect MFC gastric cancer cells to inhibit their growth and improve the anti-tumor immune activity of the tumor site.
Insights
Engineered oncolytic adenovirus Ad5-CCL19 effectively inhibits gastric cancer cell growth and activates anti-tumor immunity by enhancing T cell infiltration and cytokine secretion.
Area of Science:
- Oncolytic virotherapy
- Cancer immunology
- Gastric cancer research
Background:
- Oncolytic viruses are promising cancer therapeutics.
- CCL19 is a chemokine that attracts immune cells.
- Engineering oncolytic viruses to express immune-modulating factors is a novel strategy.
Purpose of the Study:
- To investigate the efficacy of oncolytic adenovirus Ad5-CCL19 in inhibiting gastric cancer growth.
- To evaluate the potential of Ad5-CCL19 to activate anti-tumor immune responses.
Main Methods:
- Constructed Ad5-CCL19 by inserting mouse CCL19 gene into oncolytic adenovirus Ad5.
- Assessed CCL19 expression via Western blotting.
- Evaluated cytotoxicity using MTT assays and in vivo tumor models.
- Analyzed immune cell infiltration (CD4+, CD8+) and cytokine secretion (IFN-γ, TNF-α) by immunofluorescence and flow cytometry.
Main Results:
- Ad5-CCL19 successfully infected cells and secreted CCL19.
- Demonstrated dose-dependent cytotoxicity against gastric cancer cells in vitro.
- Showed superior tumor inhibition compared to Ad5 in vivo.
- Significantly increased CD4+ and CD8+ T cell infiltration and elevated IFN-γ and TNF-α levels in tumor tissues.
Conclusions:
- Ad5-CCL19 effectively inhibits gastric cancer cell growth.
- Ad5-CCL19 enhances anti-tumor immune activity at the tumor site.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Tumor Immunotherapy

